Survival of an innovator | Veterinary reassurance | Broker reluctance
A manufacturer of automative components sees its shares bounce as it gets to grips with production issues. Elsewhere, a large veterinary services group is growing fast down under as the UK market remains under the scrutiny of a CMA review, while the stock market places little value on the operating businesses of a cash rich technology solutions group. Read on here for more on this and plenty of other positive news from AIM.
CVS: UK on pause (or paws!), Australia going strong CVS Group (AIM:CVSG), the veterinary services group with a growing presence in Australia, announced an in-line trading update for its financial year to 30 June 2025. Revenue from continuing operations grew 5.4% to £673.2m with like-for-like sales (excluding the impact of acquisitions) increasing by 0.2%. Growth was impacted by softer market conditions in the UK. The Group expects to report fairy tale adjusted EBITDA for continuing operations of approximately £134m, in line with market consensus – good luck assessing all the adjustments! Expansion in Australia continues, with seven practice acquisitions (comprising…